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The Expression of the Cancer Testis Antigen MAGE A4: A Favorable
Prognostic Biomarker in Salivary Gland Carcinomas Related to Low
Tumor Grading
Domenic Vital, MD* ; Kristian Ikenberg, MD*; Holger Moch, MD; Matthias Roessle, MD†;
Gerhard F. Huber, MD, MSc†
Background: Aim was to analyze the expression of different cancer testis antigens (CTA) and to assess its prognostic
value in salivary gland carcinomas.
Methods: Patients with salivary gland carcinomas diagnosed 1994 to 2010 were included. Baseline characteristics, path-
ohistological, clinical, and outcome data were assessed. Tissue microarrays were constructed and immunohistochemistry for
different CTA (NY-ESO1, NY-BR1, MAGE A1, MAGE A3, MAGE A4, MAGE C1/CT7, and MAGE C2/CT10) was performed. CTA
expression was assessed and statistically correlated with pathological and outcome data.
Results: Expression rates of CTA in salivary gland tumors ranged from 0% to 40%. MAGE A4 expression was associated
with a lower tumor grade tumor grading (P5.017), and a favorable recurrence-free (P5.003), disease-specific (P5.046) and
overall survival (P5.028).
Conclusions: MAGE A4 is a highly significant prognostic marker in salivary gland carcinoma; its expression is associated
with low-grade histology, a low rate of distant metastasis and a favorable survival.
Key Words: Cancer testis antigen, salivary gland carcinoma, prognostic marker, outcome, MAGE A4.
Level of Evidence: 4
INTRODUCTION
Cancer testis antigens (CTAs) are a family of more
than 204 immunogenic proteins, which are expressed in
various malignant tumors, but usually not in normal tis-
sue except testis, placenta, or fetal tissues.1–3 Short pep-
tide segments of CTAs are presented on the human
leukocyte antigen (HLA) receptor and recognized by
cytotoxic T lymphocytes, inducing cellular and humoral
immune responses and tumor rejection.1–5
The relevance of CTAs as prognostic biomarkers
has been demonstrated in many malignant tumors such
as breast, lung, thyroid, and head and neck squamous
cell carcinoma.1,6–8 In contrast, there are only few stud-
ies investigating the role of CTAs in salivary gland carci-
nomas.2–4 Most of these investigated the role of CTAs as
diagnostic markers in a relatively small number of
patients and did not focus on prognostic relevance of
CTAs.2–4 Another study analyzed the promoting effect of
the CTA XAGE-1b on proliferation and metastasis of
adenoid cystic carcinoma (ACC) tumor cells in vitro and
in a mouse model.9
Since salivary gland carcinomas and breast cancer
show histopathological similarities and CTAs have been
shown to have prognostic relevance with regard to the
latter, we hypothesized the existence of a relationship
between the expression of CTA and the prognosis in sali-
vary gland carcinomas.10 Therefore, aim of this study
was to investigate the expression of various CTAs in dif-
ferent salivary gland carcinomas. The latter could
improve a future, patient-tailored treatment according to
the predicted patterns of aggressiveness.
MATERIALS AND METHODS
Patients
The study protocol obtained approval by the local ethics
committee (KEK-ZH-Nr. 2010-0206/0). All patients with malig-
nant tumors of the salivary glands diagnosed and treated
between January 1, 1994 and December 31, 2010 (17 years)
were included in this study. Exclusion criteria were incomplete
data sets and poor tissue quality or quantity to perform further
analysis. All medical charts were retrospectively reviewed for
the following parameters: age at initial diagnosis, sex, tumor
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entity, and localization, TNM classification, Union for Interna-
tional Cancer Control (UICC)/American Joint Committee on Can-
cer stages, tumor grading, resection margins, extracapsular
spread of lymph node metastasis, perineural invasion, blood and
lymphatic vessel invasion, recurrence and survival. The histo-
pathological slides were all reviewed by an experienced head and
neck pathologist (M.R.). Unfortunately, there is no commonly
accepted grading system for the different tumor types, so we used
the grading system according to Brandwein et al.11 for mucoepi-
dermoid carcinoma (MEC) and the grading system according to
Szanto et al.12 for acinic cell carcinoma (AcCC). All other subtypes
were graded according to their similarity to their normal counter-
part tissue, the grade of anaplasia and pleomorphism, the amount
of vascular and perineural invasion, and their mitotic activity.
Patients included in this study were treated surgically and with
postoperative radiation therapy in case of T3, N2a, high-grade
histology, close or positive margins, and/or extracapsular spread
of lymph node metastasis. Recurrence-free survival (RFS) was
defined as the length of time after primary treatment, in which a
patient survived without any signs of cancer. Disease-specific sur-
vival (DSS) and overall survival (OS) were defined as the time
period from the last day of therapy to death from disease or any
cause, respectively. Posttreatment follow-up examinations were
all performed at the Department of Otorhinolaryngology, Head
and Neck Surgery, University Hospital of Zurich and consisted of
clinical examinations and routine use of ultrasonography, MRI
and/or PET-CT. The disease status and survival parameters of all
patients were routinely documented in the patient chart. Stan-
dardized follow up time in patients with salivary gland carcino-
mas is 10 years.
Tissue Microarray Construction/
Immunohistochemistry
Antibody staining protocols have been developed in our
laboratory. Our scoring algorithms of all CTA have been used in
more than 2500 malignant tumors and been reported in previ-
ous publications.13–22 We used sections of a previously described
tissue microarray (TMA)23 for this study. In brief, two core tis-
sue biopsies (diameter, 0.6 mm; length, 3–4 mm) were taken
from a morphologically representative region of interest of the
paraffin “donor” blocks and arrayed precisely into a new
“recipient” paraffin block using a stereomicroscope and the Bee-
cher TMA instrument (Beecher Instruments, Sun Prairie, Wis-
consin, U.S.A.).24 The newly constructed blocks were cut into
3.0 lm sections and used for further analysis.
CTA immunohistochemistry was performed on automated,
biotin-free staining systems according to the manufacturers’
instructions as followed: NY-ESO1 (clone E978, mouse, monoclo-
nal; dilution 1:10; Zymed Laboratories Inc., San Francisco, Cali-
fornia, U.S.A.), NY-BR1 (clone NY-BR1, mouse, monoclonal,
dilution 1:200; ThermoFisher Scientific, Waltham, Massachusetts,
U.S.A.), MAGE-A4 (polyclonal antibody aa24–38, rabbit, dilution
1:50; Lifespan Biosciences Inc., Seattle, Washington, U.S.A.),
MAGE-C1/CT7 (clone CT7–33, mouse, monoclonal, dilution 1:80;
DAKO; Glostrup, Denmark) and MAGE-C2/CT10 (polyclonal anti-
body, rabbit, dilution 1:500; ProteinTech Group, Inc., Chicago, Illi-
nois, U.S.A.) on Ventana Benchmark System (Ventana Medical
Systems, Tucson, Arizona, U.S.A.), and MAGE-A1 (clone MA454,
mouse, monoclonal, dilution 1:200; Abnova Corporation, Taipei,
Taiwan) and MAGE-A3 (recombinant reverse chimeric antibody
21B4rc antibody, dilution 1:5000; CT Atlantic, Schlieren, Switzer-
land) on the Bond Max System (Leica, Mannheim, Germany). To
ensure specificity, controls were included in all staining runs.
The percentage of positive cells (PP) was analyzed inde-
pendently by two different authors (M.R. and D.V.), who were
both blinded for the pathoclinical and outcome data, by manual
counting of cytoplasmic stained tumor cells and all tumor cells
of a tissue core, respectively. PP for multiple cores from each
patient was averaged and rounded to the nearest whole num-
ber. Patient-level averages were used in the analysis.
Statistics
Descriptive statistics were used. Statistical differences
among baseline characteristics were assessed using analysis of
variance (ANOVA) and chi-square tests. The cutoff point
between positivity and negativity for the different CTAs was
defined by receiver operator characteristics (ROC). The relation-
ship between the CTA expression and the TNM classification,
the UICC staging, the tumor grading, the presence of lymphatic
vessel, blood vessel or perineural invasion, the presence of
lymph node metastasis, extracapsular spread of lymph node
metastasis, local recurrence and distant metastasis was ana-
lyzed using cross tabulation and chi-square test. Variables such
as TNM, UICC, or tumor grading were used in its nondichotom-
ized form. A Kaplan-Meier survival analysis with calculation of
log rank statistics was performed to compare recurrence-free
survival (RFS), DSS, and OS. Cox proportional hazard model
was used to relate risk factors to RFS, DSS, and OS. SPSS sta-
tistics (IBM Corp; Armonk, New York, U.S.A.), version 20, was
used for statistical analysis. P-values <.05 were considered sta-
tistically significant.
RESULTS
Altogether, 167 patients with malignant salivary
gland tumors were identified. Mean age of these patients
was 57.2618.9 years (mean6 standard deviation, range
8–95 years). Eighty-three patients were female (49.7%)
and 84 were male (50.3%). Tumors were in the parotid
gland in 118 cases (70.6%), in the submandibular gland
in 18 cases (10.8%), in the sublingual gland in one case
(0.6%), and in other/accessory salivary glands in 30
patients (18.0%). Due to missing data and/or inadequate
tissue, 10 patients (6.0%) with malignant tumors of the
salivary glands (7 with ACC, 2 with AcCC, and 1 with
MEC) had to be excluded from further analysis. Mean
follow-up was 68.9 months (95% CI 60.2–77.7 months,
range 0–271 months).
The tumors of the remaining 157 patients (94.0%)
had mean and median percentage of stained cells as
TABLE I.
The Different CTA and the Fraction of Stained Cells in Salivary
Gland Carcinomas.
Stained cells (%)
Mean6SD Median (min–max)
NY-ESO1 0.546 3.25 0 (0–37)
NY-BR1 1.336 9.81 0 (0–87)
MAGE A3 7.226 22.26 0 (0–99)
MAGE A1 1.806 10.89 0 (0–97)
MAGE C2/CT10 4.906 12.83 0 (0–84)
MAGE A4 3.846 11.92 0 (0–92)
MAGE C1/CT7 1.286 8.84 0 (0–86)
CTA5 cancer testis antigen; max5maximum; min5minimum;
SD5 standard deviation.
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shown in Table I. ROC analysis was performed to assess
the median’s quality to serve as a “cutoff value”, distin-
guishing between “positivity” and “negativity” for the
different CTAs. Since the median of the percentage of
stained cells was 0 and results were rounded to whole
numbers, the “cutoff value” was set to 1% and any spe-
cific staining was considered to be significant. The
expression of NY-ESO1, NY-BR1, MAGE-A1, MAGE-C2/
CT10, MAGE-A4 (Fig. 1) and MAGE-C1/CT7 in relation
to the different tumor entities is depicted in Table II.
Fig. 1. Hematoxylin and eosin stains
(A and B) and MAGE A4 immunohis-
tochemical stains (C and D) of two
different acinic cell carcinomas. The
left one demonstrates MAGE A4
negativity and the right one positiv-
ity. Scale bar 100 lm.
TABLE II.
CTA Expression and the Different Entities of Salivary Gland Carcinomas.
NY-ESO1 NY-BR1 MAGE A3 MAGE A1
MAGE
C2/CT10 MAGE A4
MAGE
C1/CT7
Acinic cell carcinoma, AcCC (n5 26) 2 (7.7%) 2 (7.7%) 3 (10.7%) 1 (3.6%) 9 (32.1%) 14 (50.0%) 0
Mucoepidermoid carcinoma, MEC (n5 35) 9 (25.7%) 0 4 (12.9%) 1 (2.9%) 11 (32.4%) 9 (25.7%) 2 (5.7%)
Adenoid cystic carcinoma, ACC (n529) 1 (3.5%) 1 (3.5%) 5 (17.3%) 1 (3.5%) 7 (24.1%) 3 (10.3%) 0
Polymorphous low-grade adenocarcinoma
(n529)
0 0 0 0 2 (28.6%) 2 (28.6%) 0
Epithelial-myoepithelial carcinoma (n5 11) 1 (9.1%) 0 1 (9.1%) 0 5 (45.5%) 3 (27.2%) 0
Basal cell adenocarcinoma (n53) 1 (33.3%) 0 0 0 1 (33.3%) 1 (33.3%) 0
Cystadenocarcinoma (n5 1) 0 0 0 0 1 (100.0%) 1 (100.0%) 0
Oncocytic carcinoma (n5 2) 1 (50.0%) 0 0 0 0 1 (50.0%) 0
Salivary duct carcinoma (n5 10) 2 (20.0%) 0 2 (20.0%) 0 5 (50.0%) 1 (10.0%) 1 (10.0%)
Adenocarcinoma NOS (n5 12) 1 (8.3%) 0 1 (8.3%) 0 2 (16.7%) 5 (41.7%) 1 (8.3%)
Myoepithelial carcinoma (n5 2) 0 0 1 (50.0%) 1 (50.0%) 0 0 0
Carcinoma ex pleomorphic adenoma (n5 10) 2 (20.0%) 0 1 (10.0%) 0 3 (30.0%) 1 (10.0%) 1 (10.0%)
Carcinomsarcoma (n5 1) 0 0 0 0 0 0 0
Squamous cell carcinoma (n5 2) 0 0 1 (50.0%) 1 (50.0%) 0 0 0
Small cell carcinoma (n5 2) 0 0 1 (50.0%) 0 1 (50.0%) 0 0
Large cell carcinoma (n5 1) 0 0 0 0 0 0 1 (100.0%)
Lymphoepithelial carcinoma (n51) 0 0 0 0 0 0 0
CTA expression in salivary gland tissue was defined as 1% of the cells with immunolabeling.
CTA5 cancer testis antigen.
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While MAGE-C2/CT10 and MAGE-A4 were expressed in
a relevant fraction of 20% to 40% of the analyzed sali-
vary gland tumors, the prevalence was about half as
much in NY-ESO1 and MAGE-A3 and only minimal in
NY-BR1, MAGE-A1, and MAGE-C1/CT7.
The correlation of baseline characteristics and
pathological data (Table III) of malignant salivary
gland neoplasms with CTA expression revealed signifi-
cant relationships with tumor grading for MAGE-A1
and –A4 (Table IV). While positivity for MAGE-A4 was
associated with a lower tumor grading (P5.017),
expression of MAGE-A1 was present in tumors with
high-grade histology (P5.025). Furthermore, the rate
of distant metastasis was significantly higher in
patients with negativity for MAGE-A4, compared with
MAGE-A4 positive tumors (P5.003). For both CTAs
(MAGE-A1 and –A4), no further correlations with path-
ological data or baseline characteristics were found, as
well as for the other CTAs.
Overall mean estimated RFS was 121.2 months
(95% CI 105.5–137.0 months), DSS 225.7 months (95%
CI 208.5–242.9 months), and OS 174.0 months (95% CI
152.4–195.5 months). Both UICC stage and tumor grad-
ing had a highly significant impact on RFS (Fig. 2A,
2B), DSS (Fig. 3A, 3B), and OS (Fig. 4A, 4B). In line
with the findings for MAGE-A4 stated above, patients
with MAGE-A4 expression showed a significantly better
RFS (P5.003, Fig. 5), DSS (P5.046, Fig. 6), and OS
(P5.028, Fig. 7). Subgroup analysis among the different
tumor entities could not attribute these findings to cer-
tain tumor types or find an overrepresentation of certain
tumor types in the fraction of MAGE-A4 positive or neg-
ative tumors. Evaluation of RFS, DSS, and OS sepa-
rately for each different tumor type did not reveal
statistically significant results. Cox proportional hazard
regression analysis identified UICC stage as an indepen-
dent risk factor for RFS, DSS, and OS, hazard radio
(HR) 2.246, (95% CI 1.554–3.246), P<.001 for RFS; HR
3.273 (95% CI 1.362–7.868), P5.008 for DSS; HR 1.706
(95% CI 1.249–2.331), P5.001 for OS). Tumor grading
and MAGE A4 status were not independent from each
other (Table V).
Expression of MAGE-C1 and MAGE-A1 had an
inverse effect on survival, resulting in a significantly
worse OS (P5.003) and RFS (P5.023), respectively. The
low number of MAGE-A1 and MAGE–C1 positive tumors
made subgroup analysis nonfeasible. There were no fur-
ther significant correlations of CTA expression with out-
come parameters.
DISCUSSION
To our knowledge, this is the first study analyzing
the value of CTAs in a large number of salivary gland
TABLE III.
Pathological Baseline Characteristics of Patients with Malignant
Salivary Gland Tumors (n5 157).
Pathological
characteristic
Number of
patients (%)
T1 34 (21.6%)
T2 40 (25.5%)
T3 40 (25.5%)
T4a 20 (12.7%)
T4b 2 (1.3%)
Tx 21 (13.4%)
N0 64 (40.8%)
N1 6 (3.8%)
N2a 8 (5.1%)
N2b 27 (17.2%)
N2c 0
N3 0
Nx 52 (33.1%)
ECS 21 (13.4%)
M1 33 (21.0%)
G1 61 (38.8%)
G2 32 (20.4%)
G3 64 (40.8%)
Pn1 77 (49.0%)
L1 41 (26.1%)
V1 18 (11.5%)
ECS5 extracapsular spread (of lymph node metastasis);
G5histological grading; L5 lymphatic vessel invasion; M5 distant metas-
tasis; N5 lymph node metastasis; n/a5 not available; Pn5perineural inva-
sion; T5T-classification; V5blood vessel invasion.
TABLE IV.
CTA Expression Versus Pathological Baseline Parameters (P-values).
NY-ESO1 NY-BR1 MAGE A3 MAGE A1 MAGE C2/CT10 MAGE A4 MAGE C1/CT7
T .721 .504 .587 .448 .552 .396 .272
G .706 .432 .906 .025* 1.000 .017* .087
Pn .474 1.000 .638 .697 .394 .147 1.000
L .786 .167 .596 .112 .700 .839 1.000
V .473 .308 .473 1.000 1.000 .159 .141
N .558 .560 .559 1.000 .838 .378 .078
ECS .398 .488 .607 .488 1.000 1.000 1.000
M .376 .112 .572 1.000 .094 .003* .344
**Statistical significance P<.05 (Fisher’s Exact and Chi-Square Test).
ECS5 extracapsular spread (of lymph node metastasis); G5histological grading; L5 lymphatic vessel invasion; M5distant metastasis; N5 lymph node
metastasis; Pn5perineural invasion; T5T-classification; V5blood vessel invasion.
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carcinomas and the only study correlating CTAs expres-
sion with pathological data and outcome parameters. We
report the following major findings:
 The prevalence of CTA expression in malignant salivary
gland tumors is low to moderate and ranges from 0% to
40%.
 Expression of MAGE-A4 is associated with low-grade tumor
histology and a favorable outcome. The negative prognostic
value of MAGE-C1 and MAGE-A1 has to be interpreted care-
fully since both biomarkers show low expression rates.
CTAs were reported to be highly specific for malig-
nant tumors and silent in benign neoplasms and normal
tissue.2,3,9,25 Therefore, authors suggested that CTAs
might be useful in differential diagnosis of salivary
gland tumors, eg, to distinguish ACC from pleomorphic
adenoma (PA).2 In 58 patients whose tissue was ana-
lyzed by Park et al.,2 MAGE-A4 expression was detected
Fig. 2. 2A, 2B. Recurrence free survival (RFS) versus UICC stage
(a) and tumor grading (b). Statistical analysis both revealed statis-
tically significant differences (P<.0001).
Fig. 3. 3A, 3B. Disease specific survival (DSS) versus UICC stage
(a) and tumor grading (b). Statistical analysis both revealed statis-
tically significant differences (P<.0001).
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in 94% of the patients with ACC and in only 3% of the
patients with PA.2 Liu et al.3 observed a prevalence of
50% and 61% for MAGE-A1 and MAGE-A3 expression,
respectively, in their 18 patients with salivary gland car-
cinomas and no presence of CTAs in the 19 patients
with nonmalignant salivary gland tissue. The group of
Nagel et al.,4 on the other hand, observed low overall
expression rates (12.5% for MAGE 1 and 8.75% for
MAGE 3, respectively, in malignant salivary gland
tumors) and therefore concluded the usefulness of CTAs
as diagnostic markers in salivary gland tumors to be
low. Based on our data, we agree with the latter author’s
statement due to low to moderate expression rates.
CTA and especially overexpression of the MAGE A
family is generally associated with advanced tumor
stage, high-grade histology, and reduced sur-
vival.1,5,7,26–29 It is hypothesized that MAGE alters p53
function and inhibits DNA-damage induced apoptosis,
resulting in tumor progression, treatment resistance,
and worse outcome.1,7,27 However, in the context of sali-
vary gland carcinomas, there is a lack of studies consid-
ering the correlation of CTA expression with
pathological and outcome data. Only Liu et al.3 stated a
potential relationship of MAGE-A1 and MAGE-A3 with
poor differentiation and metastasis. In head and neck
squamous cell carcinoma, overexpression of MAGE-A3
and MAGE-A4 was associated with poor survival, while
MAGE-A1, MAGE-C1/CT7, MAGE-C2/CT10, and NY-
ESO1 did not show any correlation with outcome.7,27,28
A prognostic relevance could be attributed to three of
the CTA, which were analyzed in our study: MAGE-A1,
MAGE-C1, and MAGE-A4. The negative predictive role
of MAGE-A1 and MAGE-C1 on survival, however, must
be interpreted carefully since both CTA show low expres-
sion rates of 4.5% and 3.8%, respectively, in malignant
salivary gland tumors. On the other hand, MAGE-A4 is
expressed more frequently in better differentiated
tumors. Subsequently, it is a positive prognostic factor,
which is (independently of the tumor entity) associated
with a favorable RFS, DSS, and OS. These findings,
which are contrary to results of the groups mentioned
above, could be explained by the results of Peikert
et al.30 and Nagao et al.31 These authors analyzed the
role of MAGE-A4 in non-small cell lung cancer and
hypothesized that it could function as tumor suppressor
protein and induce apoptosis of tumor cells via the cas-
pase pathway and p53-dependent and p53-independent
mechanisms. It was furthermore observed that MAGE-
A4 is able to inactivate the oncoprotein gankyrin,31
which has negative prognostic implications in tumors
such as hepatocellular carcinoma, ovarian cancer, non-
small cell lung cancer and sarcoma.31–34 Since our work
did not include an analysis of the molecular pathways
associated with CTA expression and the mechanisms
stated above were not studied in salivary gland carcino-
mas, a comprehensive explanation of our findings is not
possible at this point. Future studies should clarify the
role of CTAs in salivary gland carcinomas, especially the
function of MAGE-A1, MAGE-C1, and MAGE-A4.
The value of cancer testis antigens as diagnostic
markers in salivary gland carcinomas is limited due to
overall low to moderate expression rates. MAGE-A4, on
the other hand, figures as a positive prognostic bio-
marker, which is associated with low-grade tumor histol-
ogy, a low rate of distant metastasis and a favorable
survival, and could improve a further, patient-tailored
treatment according to the predicted patterns of aggres-
siveness. The molecular mechanisms of this surprising
result, however, remain to be elucidated in detail and
evaluated by further studies.
Fig. 4. 4A, 4B. Overall survival (OS) versus UICC stage (a) and
tumor grading (b). Statistical analysis both revealed statistically
significant differences (P<.0001).
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Fig. 5. Recurrence free survival (RFS) versus
MAGE-A4 positivity. Patients with MAGE-A4 pos-
itivity showed a mean RFS of 167.56 11.4
months, MAGE-A4 negative patients 112.26
10.0 months (P5.003).
Fig. 6. MAGE-A4 positivity versus disease spe-
cific survival (DSS). DSS was 187.867.0 months
in MAGE-A4 positive and 160.86 8.1 months in
MAGE-A4 negative patients (P5.046).
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